Status:

COMPLETED

Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as TREXIMA, for Menstrual Migraine in Women With Dysmenorrhea

Lead Sponsor:

GlaxoSmithKline

Conditions:

Migraine Disorders

Eligibility:

FEMALE

18-65 years

Phase:

PHASE3

Brief Summary

This study was designed to determine efficacy of TREXIMA compared to placebo for the treatment of a menstrual migraine.

Detailed Description

A randomized, double-blind, single migraine attack, placebo-controlled, parallel group, multicenter study to evaluate the efficacy and tolerability of TREXIMA\* (sumatriptan succinate/naproxen sodium)...

Eligibility Criteria

Inclusion

  • At least a 6 month history of physician diagnosed migraine and typically experiences 2-6 migraine attacks per month.
  • Typically experiences moderate to severe migraine pain preceded by a mild pain phase.
  • Differentiate between mild migraine pain and other headache types.
  • Women of childbearing potential must be on adequate contraception.

Exclusion

  • Pregnant and/or nursing mother.
  • History of cardiovascular disease.
  • Uncontrolled hypertension.
  • Basilar or Hemiplegic migraine.
  • History of stroke or transient ischemic attacks (TIA).
  • History of epilepsy or treated with anti-epileptics within past 5 years.
  • Impaired hepatic or renal function.
  • History of gastrointestinal bleeding or ulceration.
  • Allergy or hypersensitivity to aspirin or any other NSAID.
  • Allergy or hypersensitivity to triptans.
  • Participated in an investigational drug trial in the previous 4 weeks.

Key Trial Info

Start Date :

May 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 1 2006

Estimated Enrollment :

320 Patients enrolled

Trial Details

Trial ID

NCT00329459

Start Date

May 1 2006

End Date

November 1 2006

Last Update

October 24 2016

Active Locations (34)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 9 (34 locations)

1

GSK Investigational Site

Mesa, Arizona, United States, 85201

2

GSK Investigational Site

Little Rock, Arkansas, United States, 72205

3

GSK Investigational Site

Fair Oaks, California, United States, 95628

4

GSK Investigational Site

Newport Beach, California, United States, 92660